These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14974348)

  • 1. [New antiretroviral medications in therapy of HIV infections].
    Lipniacki A; Piasek A
    Przegl Lek; 2003; 60(8):536-41. PubMed ID: 14974348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in antiretroviral therapy in HIV infection.
    Arora DR; Gautam V; Gill PS; Mishra N
    J Indian Med Assoc; 2010 Jan; 108(1):29-34. PubMed ID: 20839577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug targets for HIV.
    Bean P
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S96-100. PubMed ID: 16265623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on HAART in HIV.
    Yeni P
    J Hepatol; 2006; 44(1 Suppl):S100-3. PubMed ID: 16359748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapy of HIV.
    Potthoff AV; Brockmeyer NH
    J Dtsch Dermatol Ges; 2010 Jan; 8(1):45-56; quiz 57-8. PubMed ID: 20096060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
    Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
    J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.
    Justesen US
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):20-31. PubMed ID: 16433887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
    Jones R; Gazzard B
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):303-12. PubMed ID: 16597210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Revised guideline "Antiretroviral Treatment"].
    Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2399-405. PubMed ID: 16277129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity.
    Di Santo R; Costi R; Artico M; Ragno R; Greco G; Novellino E; Marchand C; Pommier Y
    Farmaco; 2005 May; 60(5):409-17. PubMed ID: 15910813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
    J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current developments in HIV chemotherapy.
    Meadows DC; Gervay-Hague J
    ChemMedChem; 2006 Jan; 1(1):16-29. PubMed ID: 16892329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.